Regeneron Pharmaceuticals, Inc. (REGN) is a Biotechnology company in the Healthcare sector, currently trading at $753.93. It has a SharesGrow Score of 83/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of REGN = $1,711.01 (+126.9% from the current price, the stock appears undervalued). Analyst consensus target is REGN = $863 (+14.4% upside).
Valuation: REGN trades at a trailing Price-to-Earnings (P/E) of 17.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.04.
Financials: revenue is $14.3B, +5.7%/yr average growth. Net income is $4.5B, growing at +1.6%/yr. Net profit margin is 31.4% (strong). Gross margin is 85.4% (-1.8 pp trend).
Balance sheet: total debt is $2.7B against $31.3B equity (Debt-to-Equity (D/E) ratio 0.09, conservative). Current ratio is 4.13 (strong liquidity). Debt-to-assets is 6.7%. Total assets: $40.6B.
Analyst outlook: 34 / 48 analysts rate REGN as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 55/100 (Partial), Past 100/100 (Pass), Health 100/100 (Pass), Moat 80/100 (Pass), Future 73/100 (Pass), Income 100/100 (Pass).
